As shown in Figure 5A, there was no significant difference in MM tumor burden at the experimental endpoint as measured by bioluminescent imaging (BLI) (p = 0.4399, median BLI; IgG control antibody, 1.14 × 107 photons/sec (interquartile range: 1.16 × 106–1.39 × 108) vs. anti-Grem1 antibody, 1.40 × 107 photons/sec (interquartile range: 1.12 × 106–1.02 × 108) (Figure 5A). This evidence concerns the gene GREM1 and Miyoshi myopathy.